These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 12728284)

  • 21. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
    Paul C; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
    [No Abstract]   [Full Text] [Related]  

  • 22. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
    Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V
    Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept.
    Wolf P; Hofer A; Legat FJ; Bretterklieber A; Weger W; Salmhofer W; Kerl H
    Br J Dermatol; 2009 Jan; 160(1):186-9. PubMed ID: 19067710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study.
    Mazzotta A; Esposito M; Schipani C; Chimenti S
    J Dermatolog Treat; 2009; 20(6):354-8. PubMed ID: 19954392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
    Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B
    Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy study on etanercept in patients with plaque psoriasis.
    Costanzo A; Mazzotta A; Papoutsaki M; Nisticò S; Chimenti S
    Br J Dermatol; 2005 Jan; 152(1):187-9. PubMed ID: 15656833
    [No Abstract]   [Full Text] [Related]  

  • 28. Inhibitors of tumor necrosis factor for rheumatoid arthritis.
    Moreland LW
    J Rheumatol Suppl; 1999 May; 57():7-15. PubMed ID: 10328137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The medical uses and side effects of etanercept with a focus on cutaneous disease.
    Scheinfeld N
    J Drugs Dermatol; 2004; 3(6):653-9. PubMed ID: 15624748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of erythrodermic psoriasis with etanercept.
    Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
    Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept].
    Mahiques L; Pitarch G; Sánchez-Carazo JL; Pérez-Ferriols A; Soriano CJ; Alegre V
    Actas Dermosifiliogr; 2007 Oct; 98(8):539-44. PubMed ID: 17919428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etanercept provides a more physiological approach in the treatment of psoriasis.
    Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept.
    Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Stramazzotti D; Morichetti D; Bernardini ML; Mannello B; Fabris G; Offidani A
    Br J Dermatol; 2007 Dec; 157(6):1155-60. PubMed ID: 17916208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etanercept: an evolving role in psoriasis and psoriatic arthritis.
    Prodanovich S; Ricotti C; Glick BP; Inverardi L; Leonardi CL; Kerdel F
    Am J Clin Dermatol; 2010; 11 Suppl 1():3-9. PubMed ID: 20586498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
    Leonardi C; Strober B; Gottlieb AB; Elewski BE; Ortonne JP; van de Kerkhof P; Chiou CF; Dunn M; Jahreis A
    J Drugs Dermatol; 2010 Aug; 9(8):928-37. PubMed ID: 20684143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etanercept for the treatment of psoriasis and psoriatic arthritis.
    Gottlieb AB
    Dermatol Ther; 2004; 17(5):401-8. PubMed ID: 15379775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus.
    Martínez-Abundis E; Reynoso-von Drateln C; Hernández-Salazar E; González-Ortiz M
    Arch Dermatol Res; 2007 Nov; 299(9):461-5. PubMed ID: 17726611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etanercept for psoriasis in the pediatric population: experience in nine patients.
    Hawrot AC; Metry DW; Theos AJ; Levy ML
    Pediatr Dermatol; 2006; 23(1):67-71. PubMed ID: 16445417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.